What is the clinical evidence from this study?

Study design: Other. Population: Dabigatran-induced coagulopathy (n=8). Intervention: FEIBA. Primary outcome: Thrombin generation parameters.

What question did this study set out to answer?

The aim is to evaluate the effectiveness of FEIBA in correcting coagulation abnormalities caused by dabigatran.

September 28, 2012International Journal of Laboratory HematologyOpen Access

The use of FEIBA® in the correction of coagulation abnormalities induced by dabigatran

View Full Paper

Ask AI

Bookmark

Key result

Ex-vivo spiking with FEIBA improved abnormal thrombin generation parameters in the plasma of patients on dabigatran.

Why the study?

Does ex-vivo spiking with anti-inhibitor coagulant complex (FEIBA) improve thrombin generation parameters in plasma from patients on dabigatran?

Population

Plasma of patients on dabigatran (n=8)

Design

Preclinical

Authors

TKTeh‐Liane KhooRoyal Prince Alfred Hospital CWClaire WeatherburnQueensland Health GKGeoffrey KershawRoyal Prince Alfred Hospital

Discussion

Member takes

Implication

FEIBA alters thrombin generation ex vivo in dabigatran plasma; leaves open clinical reversal utility pending trials.

Key Points

The aim is to evaluate the effectiveness of FEIBA in correcting coagulation abnormalities caused by dabigatran.
Examined the effects of FEIBA on thrombin generation in patients on dabigatran (n=8).
Utilized calibrated automated thrombography (CAT) to measure thrombin generation parameters.
FEIBA significantly improved thrombin generation parameters altered by dabigatran.
Provided evidence for potential haemostatic support in dabigatran-induced coagulopathy.

Structured PICO

Does ex-vivo spiking with anti-inhibitor coagulant complex (FEIBA) improve thrombin generation parameters in plasma from patients on dabigatran?

Population

8 patients on dabigatran whose plasma was evaluated for thrombin generation parameters after ex-vivo spiking with FEIBA.

Intervention

Ex-vivo spiking with anti-inhibitor coagulant complex (FEIBA)

Outcome

Thrombin generation parameters measured using calibrated automated thrombography (CAT)surrogate

Ex-vivo spiking with FEIBA improves thrombin generation parameters in plasma from patients on dabigatran, suggesting potential utility for hemostatic support.

Cite This Study

Khoo et al. (2012) studied Dabigatran-induced coagulopathy (n=8). FEIBA was evaluated on Thrombin generation parameters. Ex-vivo spiking with FEIBA improved abnormal thrombin generation parameters in the plasma of patients on dabigatran.

synapsesocial.com/papers/6a62231db8c7ca59867d8f8a https://doi.org/10.1111/ijlh.12005

View Full Paper

Ask AI

Bookmark

The use of FEIBA® in the correction of coagulation abnormalities induced by dabigatran

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

The use of FEIBA® in the correction of coagulation abnormalities induced by dabigatran

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider